Cargando…

Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production

The vast majority of commercially available inactivated influenza vaccines are produced from egg-grown or cell-grown live influenza virus. The first step in the production process is virus inactivation with β-propiolactone (BPL) or formaldehyde (FA). Recommendations for production of inactivated vac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrera-Rodriguez, José, Signorazzi, Aurora, Holtrop, Marijke, de Vries-Idema, Jacqueline, Huckriede, Anke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115651/ https://www.ncbi.nlm.nih.gov/pubmed/30765167 http://dx.doi.org/10.1016/j.vaccine.2019.01.086

Ejemplares similares

Innate Responses Induced by Whole Inactivated Virus or Subunit Influenza Vaccines in Cultured Dendritic Cells Correlate with Immune Responses In Vivo
por: Stoel, Maaike, et al.
Publicado: (2015)

Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines
por: Dong, Wei, et al.
Publicado: (2018)

In Vitro Characterization of the Innate Immune Pathways Engaged by Live and Inactivated Tick-Borne Encephalitis Virus
por: Signorazzi, Aurora, et al.
Publicado: (2021)

Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization
por: Bhide, Yoshita, et al.
Publicado: (2019)

Distinctive Responses in an In Vitro Human Dendritic Cell-Based System upon Stimulation with Different Influenza Vaccine Formulations
por: Tapia-Calle, Gabriela, et al.
Publicado: (2017)

Enhancement of the Immunogenicity and Protective Efficacy of a Mucosal Influenza Subunit Vaccine by the Saponin Adjuvant GPI-0100
por: Liu, Heng, et al.
Publicado: (2012)

Evaluation of Mucosal and Systemic Immune Responses Elicited by GPI-0100- Adjuvanted Influenza Vaccine Delivered by Different Immunization Strategies
por: Liu, Heng, et al.
Publicado: (2013)

Characterization of humoral immune responses and degree of protection induced by influenza vaccine in cotton rats: Effects of low vaccine dose and single vs booster vaccination
por: Bhide, Yoshita, et al.
Publicado: (2020)

Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation
por: Patil, Harshad P., et al.
Publicado: (2017)

Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs
por: Geeraedts, Felix, et al.
Publicado: (2008)

Comparison of media for a human peripheral blood mononuclear cell-based in vitro vaccine evaluation system
por: Gong, Shuran, et al.
Publicado: (2023)

Heterosubtypic cross‐protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration
por: Budimir, Natalija, et al.
Publicado: (2013)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China
por: Chen, Yaping, et al.
Publicado: (2022)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

Prolonging the delivery of influenza virus vaccine improves the quantity and quality of the induced immune responses in mice
por: Beukema, Martin, et al.
Publicado: (2023)

Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines
por: Sridhar, Saranya, et al.
Publicado: (2015)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen
por: Tsunetsugu-Yokota, Yasuko
Publicado: (2007)

Induction of Heterosubtypic Cross-Protection against Influenza by a Whole Inactivated Virus Vaccine: The Role of Viral Membrane Fusion Activity
por: Budimir, Natalija, et al.
Publicado: (2012)

Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21
por: Syrkina, Olga, et al.
Publicado: (2022)

Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine
por: Zhang, Zhegang, et al.
Publicado: (2022)

1059 Expanded immunogenicity of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine in older adults
por: Diazgranados, Carlos, et al.
Publicado: (2014)

Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus
por: Bhide, Yoshita, et al.
Publicado: (2018)

2743. Safety of Recombinant Influenza Vaccine Compared with Inactivated Influenza Vaccine in Adults
por: Hansen, John, et al.
Publicado: (2019)

Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine
por: Infimate, DJ L, et al.
Publicado: (2022)

Preservation of the Immunogenicity of Dry-powder Influenza H5N1 Whole Inactivated Virus Vaccine at Elevated Storage Temperatures
por: Geeraedts, Felix, et al.
Publicado: (2010)

Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season
por: Chabanon, Anne-Laure, et al.
Publicado: (2021)

The evolution of humoral immune responses to past and novel influenza virus strains gives evidence for antigenic seniority
por: Sicca, Federica, et al.
Publicado: (2022)

Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling
por: Geeraedts, Felix, et al.
Publicado: (2008)

Critical Role of TLR7 Signaling in the Priming of Cross-Protective Cytotoxic T Lymphocyte Responses by a Whole Inactivated Influenza Virus Vaccine
por: Budimir, Natalija, et al.
Publicado: (2013)

Safety of Recombinant Influenza Vaccine Compared to Inactivated Influenza Vaccine in Adults: An Observational Study
por: Hansen, John, et al.
Publicado: (2020)

High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors
por: Becker, Debbie L., et al.
Publicado: (2016)

Long-Term Immunogenicity Studies of Formalin-Inactivated Enterovirus 71 Whole-Virion Vaccine in Macaques
por: Liu, Chia-Chyi, et al.
Publicado: (2014)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Low immunogenicity of whole virion, verocell-derived, inactivated, pandemic influenza H1N1 vaccine in HIV-infected patients
por: Lagler, H, et al.
Publicado: (2010)

Central retinal artery occlusion after vaccination with whole virion inactivated SARSCoV- 2 vaccine Covaxin
por: Thakar, Meenakshi, et al.
Publicado: (2022)

Complexes of Zinc With Picolinic and Aspartic Acids Inactivate Free Varicella-Zoster Virions
por: Shishkov, S., et al.
Publicado: (1996)

Effect of Inactivation Methods on SARS-CoV-2 Virion Protein and Structure
por: Loveday, Emma K., et al.
Publicado: (2021)

Enhanced passive safety surveillance of high‐dose and standard‐dose quadrivalent inactivated split‐virion influenza vaccines in Germany and Finland during the influenza season 2021/22
por: Gandhi‐Banga, Sonja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ild512n81g9kkvk3gs5pg1satv